nodes	percent_of_prediction	percent_of_DWPC	metapath
Ergotamine—HTR2A—conduct disorder	0.816	1	CbGaD
Ergotamine—SLC6A2—autonomic nervous system—conduct disorder	0.00551	0.288	CbGeAlD
Ergotamine—HTR2A—autonomic nervous system—conduct disorder	0.00331	0.173	CbGeAlD
Ergotamine—Lisuride—DRD4—conduct disorder	0.00244	0.245	CrCbGaD
Ergotamine—Bromocriptine—DRD4—conduct disorder	0.00226	0.227	CrCbGaD
Ergotamine—Methylergometrine—HTR2A—conduct disorder	0.00168	0.169	CrCbGaD
Ergotamine—HTR1F—brain—conduct disorder	0.00162	0.085	CbGeAlD
Ergotamine—HTR1E—brain—conduct disorder	0.00141	0.0737	CbGeAlD
Ergotamine—Methysergide—HTR2A—conduct disorder	0.0014	0.141	CrCbGaD
Ergotamine—Lisuride—HTR2A—conduct disorder	0.00113	0.113	CrCbGaD
Ergotamine—Bromocriptine—HTR2A—conduct disorder	0.00104	0.105	CrCbGaD
Ergotamine—ADRA1B—brain—conduct disorder	0.000881	0.0461	CbGeAlD
Ergotamine—ADRA1D—brain—conduct disorder	0.000862	0.0451	CbGeAlD
Ergotamine—HTR1B—brain—conduct disorder	0.000666	0.0348	CbGeAlD
Ergotamine—HTR1D—brain—conduct disorder	0.000644	0.0337	CbGeAlD
Ergotamine—HTR2C—brain—conduct disorder	0.000638	0.0334	CbGeAlD
Ergotamine—HTR2B—brain—conduct disorder	0.000599	0.0314	CbGeAlD
Ergotamine—HTR1A—brain—conduct disorder	0.000537	0.0281	CbGeAlD
Ergotamine—SLC6A2—brain—conduct disorder	0.000533	0.0279	CbGeAlD
Ergotamine—ADRA1A—brain—conduct disorder	0.000495	0.0259	CbGeAlD
Ergotamine—DRD2—brain—conduct disorder	0.000485	0.0254	CbGeAlD
Ergotamine—ADRA2A—brain—conduct disorder	0.000376	0.0197	CbGeAlD
Ergotamine—HTR2A—brain—conduct disorder	0.00032	0.0168	CbGeAlD
Ergotamine—HTR1F—GPCR ligand binding—HTR2A—conduct disorder	0.000225	0.00145	CbGpPWpGaD
Ergotamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000224	0.00144	CbGpPWpGaD
Ergotamine—HTR1D—GPCR downstream signaling—CGA—conduct disorder	0.000222	0.00143	CbGpPWpGaD
Ergotamine—DRD2—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000221	0.00143	CbGpPWpGaD
Ergotamine—HTR1D—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00022	0.00142	CbGpPWpGaD
Ergotamine—HTR1D—GPCR ligand binding—DRD4—conduct disorder	0.00022	0.00142	CbGpPWpGaD
Ergotamine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.000218	0.00141	CbGpPWpGaD
Ergotamine—HTR1B—GPCR downstream signaling—CGA—conduct disorder	0.000218	0.0014	CbGpPWpGaD
Ergotamine—HTR2A—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000218	0.0014	CbGpPWpGaD
Ergotamine—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000216	0.00139	CbGpPWpGaD
Ergotamine—HTR1B—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000216	0.00139	CbGpPWpGaD
Ergotamine—HTR1B—GPCR ligand binding—DRD4—conduct disorder	0.000216	0.00139	CbGpPWpGaD
Ergotamine—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000215	0.00138	CbGpPWpGaD
Ergotamine—ADRA2A—G alpha (i) signalling events—DRD4—conduct disorder	0.000213	0.00137	CbGpPWpGaD
Ergotamine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000213	0.00137	CbGpPWpGaD
Ergotamine—HTR1E—GPCR ligand binding—HTR2A—conduct disorder	0.000212	0.00137	CbGpPWpGaD
Ergotamine—HTR2C—G alpha (q) signalling events—HTR2A—conduct disorder	0.000212	0.00136	CbGpPWpGaD
Ergotamine—ABCB1—brain—conduct disorder	0.00021	0.011	CbGeAlD
Ergotamine—CYP1A2—Phase II conjugation—COMT—conduct disorder	0.000208	0.00134	CbGpPWpGaD
Ergotamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000206	0.00132	CbGpPWpGaD
Ergotamine—HTR2B—GPCR downstream signaling—CGA—conduct disorder	0.000205	0.00132	CbGpPWpGaD
Ergotamine—HTR2B—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000203	0.00131	CbGpPWpGaD
Ergotamine—HTR2B—GPCR ligand binding—DRD4—conduct disorder	0.000203	0.00131	CbGpPWpGaD
Ergotamine—ADRA1B—G alpha (q) signalling events—HTR2A—conduct disorder	0.000203	0.00131	CbGpPWpGaD
Ergotamine—HTR1D—Signaling by GPCR—CGA—conduct disorder	0.000202	0.0013	CbGpPWpGaD
Ergotamine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000198	0.00128	CbGpPWpGaD
Ergotamine—HTR1B—Signaling by GPCR—CGA—conduct disorder	0.000198	0.00127	CbGpPWpGaD
Ergotamine—HTR1F—GPCR downstream signaling—DRD4—conduct disorder	0.000195	0.00125	CbGpPWpGaD
Ergotamine—ADRA1D—GPCR downstream signaling—CGA—conduct disorder	0.00019	0.00123	CbGpPWpGaD
Ergotamine—DRD2—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00019	0.00122	CbGpPWpGaD
Ergotamine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.000189	0.00122	CbGpPWpGaD
Ergotamine—HTR1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000189	0.00122	CbGpPWpGaD
Ergotamine—ADRA1D—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000189	0.00122	CbGpPWpGaD
Ergotamine—ADRA1D—GPCR ligand binding—DRD4—conduct disorder	0.000189	0.00122	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—CGA—conduct disorder	0.000187	0.0012	CbGpPWpGaD
Ergotamine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000187	0.0012	CbGpPWpGaD
Ergotamine—HTR2B—Signaling by GPCR—CGA—conduct disorder	0.000186	0.0012	CbGpPWpGaD
Ergotamine—HTR1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000185	0.00119	CbGpPWpGaD
Ergotamine—HTR1E—GPCR downstream signaling—DRD4—conduct disorder	0.000184	0.00118	CbGpPWpGaD
Ergotamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000183	0.00118	CbGpPWpGaD
Ergotamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.000181	0.00117	CbGpPWpGaD
Ergotamine—ADRA1A—G alpha (q) signalling events—HTR2A—conduct disorder	0.00018	0.00116	CbGpPWpGaD
Ergotamine—HTR1F—Signaling by GPCR—DRD4—conduct disorder	0.000177	0.00114	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—CGA—conduct disorder	0.000176	0.00113	CbGpPWpGaD
Ergotamine—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000176	0.00113	CbGpPWpGaD
Ergotamine—HTR2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000174	0.00112	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—CGA—conduct disorder	0.000173	0.00111	CbGpPWpGaD
Ergotamine—ADRA2B—GPCR downstream signaling—CGA—conduct disorder	0.000172	0.00111	CbGpPWpGaD
Ergotamine—ADRA2B—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00017	0.0011	CbGpPWpGaD
Ergotamine—ADRA2B—GPCR ligand binding—DRD4—conduct disorder	0.00017	0.0011	CbGpPWpGaD
Ergotamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00017	0.00109	CbGpPWpGaD
Ergotamine—HTR1E—Signaling by GPCR—DRD4—conduct disorder	0.000167	0.00107	CbGpPWpGaD
Ergotamine—HTR1A—GPCR downstream signaling—CGA—conduct disorder	0.000166	0.00107	CbGpPWpGaD
Ergotamine—HTR2C—GPCR downstream signaling—CGA—conduct disorder	0.000165	0.00106	CbGpPWpGaD
Ergotamine—HTR1A—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000164	0.00106	CbGpPWpGaD
Ergotamine—HTR1A—GPCR ligand binding—DRD4—conduct disorder	0.000164	0.00106	CbGpPWpGaD
Ergotamine—HTR2C—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000164	0.00105	CbGpPWpGaD
Ergotamine—HTR2C—GPCR ligand binding—DRD4—conduct disorder	0.000164	0.00105	CbGpPWpGaD
Ergotamine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000162	0.00104	CbGpPWpGaD
Ergotamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.000161	0.00104	CbGpPWpGaD
Ergotamine—ADRA1B—GPCR downstream signaling—CGA—conduct disorder	0.000158	0.00102	CbGpPWpGaD
Ergotamine—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000157	0.00101	CbGpPWpGaD
Ergotamine—ADRA1B—GPCR ligand binding—DRD4—conduct disorder	0.000157	0.00101	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—CGA—conduct disorder	0.000156	0.00101	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—CGA—conduct disorder	0.000151	0.000971	CbGpPWpGaD
Ergotamine—CYP1A2—Aryl Hydrocarbon Receptor—EP300—conduct disorder	0.00015	0.000967	CbGpPWpGaD
Ergotamine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—conduct disorder	0.00015	0.000967	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—CGA—conduct disorder	0.00015	0.000966	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—WASF1—conduct disorder	0.00015	0.000963	CbGpPWpGaD
Ergotamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000146	0.00094	CbGpPWpGaD
Ergotamine—DRD2—GPCR downstream signaling—CGA—conduct disorder	0.000146	0.000938	CbGpPWpGaD
Ergotamine—DRD2—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000144	0.00093	CbGpPWpGaD
Ergotamine—DRD2—GPCR ligand binding—DRD4—conduct disorder	0.000144	0.00093	CbGpPWpGaD
Ergotamine—HTR1D—GPCR ligand binding—HTR2A—conduct disorder	0.000144	0.000927	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—CGA—conduct disorder	0.000144	0.000924	CbGpPWpGaD
Ergotamine—HTR2A—GPCR downstream signaling—CGA—conduct disorder	0.000143	0.000923	CbGpPWpGaD
Ergotamine—HTR2A—GPCR ligand binding—DRD4—conduct disorder	0.000142	0.000915	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—WASF1—conduct disorder	0.000141	0.000909	CbGpPWpGaD
Ergotamine—ABCB1—HIF-1-alpha transcription factor network—EP300—conduct disorder	0.000141	0.000908	CbGpPWpGaD
Ergotamine—HTR1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000141	0.000908	CbGpPWpGaD
Ergotamine—HTR1B—GPCR ligand binding—HTR2A—conduct disorder	0.000141	0.000907	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR downstream signaling—CGA—conduct disorder	0.00014	0.000904	CbGpPWpGaD
Ergotamine—HTR2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00014	0.000903	CbGpPWpGaD
Ergotamine—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000139	0.000896	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR ligand binding—DRD4—conduct disorder	0.000139	0.000896	CbGpPWpGaD
Ergotamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000134	0.000864	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—CGA—conduct disorder	0.000132	0.000852	CbGpPWpGaD
Ergotamine—HTR2B—GPCR ligand binding—HTR2A—conduct disorder	0.000132	0.000852	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—CGA—conduct disorder	0.00013	0.00084	CbGpPWpGaD
Ergotamine—HTR1A—SIDS Susceptibility Pathways—EP300—conduct disorder	0.00013	0.000839	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—CGA—conduct disorder	0.00013	0.000839	CbGpPWpGaD
Ergotamine—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000129	0.000833	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR ligand binding—DRD4—conduct disorder	0.000129	0.000833	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—CGA—conduct disorder	0.000127	0.000821	CbGpPWpGaD
Ergotamine—HTR1F—GPCR downstream signaling—HTR2A—conduct disorder	0.000127	0.000819	CbGpPWpGaD
Ergotamine—HTR1D—GPCR downstream signaling—DRD4—conduct disorder	0.000125	0.000802	CbGpPWpGaD
Ergotamine—DRD2—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000124	0.000797	CbGpPWpGaD
Ergotamine—ADRA1D—GPCR ligand binding—HTR2A—conduct disorder	0.000123	0.000793	CbGpPWpGaD
Ergotamine—HTR1B—GPCR downstream signaling—DRD4—conduct disorder	0.000122	0.000786	CbGpPWpGaD
Ergotamine—CYP1A2—Biological oxidations—COMT—conduct disorder	0.000122	0.000785	CbGpPWpGaD
Ergotamine—CYP1A2—Biological oxidations—MAOA—conduct disorder	0.000121	0.00078	CbGpPWpGaD
Ergotamine—CYP1A2—Metapathway biotransformation—COMT—conduct disorder	0.00012	0.000775	CbGpPWpGaD
Ergotamine—HTR1E—GPCR downstream signaling—HTR2A—conduct disorder	0.00012	0.000772	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—CGA—conduct disorder	0.000119	0.000769	CbGpPWpGaD
Ergotamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000119	0.000768	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—CGA—conduct disorder	0.000118	0.000763	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—CGA—conduct disorder	0.000117	0.000753	CbGpPWpGaD
Ergotamine—ABCB1—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.000116	0.000746	CbGpPWpGaD
Ergotamine—HTR1F—Signaling by GPCR—HTR2A—conduct disorder	0.000115	0.000744	CbGpPWpGaD
Ergotamine—HTR2B—GPCR downstream signaling—DRD4—conduct disorder	0.000115	0.000738	CbGpPWpGaD
Ergotamine—HTR1D—Signaling by GPCR—DRD4—conduct disorder	0.000113	0.000729	CbGpPWpGaD
Ergotamine—HTR2A—SIDS Susceptibility Pathways—EP300—conduct disorder	0.000113	0.000725	CbGpPWpGaD
Ergotamine—ADRA2B—GPCR ligand binding—HTR2A—conduct disorder	0.000111	0.000716	CbGpPWpGaD
Ergotamine—HTR1B—Signaling by GPCR—DRD4—conduct disorder	0.000111	0.000714	CbGpPWpGaD
Ergotamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000111	0.000713	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—CGA—conduct disorder	0.00011	0.000707	CbGpPWpGaD
Ergotamine—HTR1E—Signaling by GPCR—HTR2A—conduct disorder	0.000109	0.000701	CbGpPWpGaD
Ergotamine—HTR1A—GPCR ligand binding—HTR2A—conduct disorder	0.000107	0.000691	CbGpPWpGaD
Ergotamine—HTR2C—GPCR ligand binding—HTR2A—conduct disorder	0.000107	0.000688	CbGpPWpGaD
Ergotamine—ADRA1D—GPCR downstream signaling—DRD4—conduct disorder	0.000107	0.000687	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—DRD4—conduct disorder	0.000105	0.000673	CbGpPWpGaD
Ergotamine—HTR2B—Signaling by GPCR—DRD4—conduct disorder	0.000104	0.00067	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.000104	0.000668	CbGpPWpGaD
Ergotamine—ADRA1B—GPCR ligand binding—HTR2A—conduct disorder	0.000102	0.000658	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—CGA—conduct disorder	0.000102	0.000658	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—DRD4—conduct disorder	9.86e-05	0.000635	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—DRD4—conduct disorder	9.68e-05	0.000624	CbGpPWpGaD
Ergotamine—ADRA2B—GPCR downstream signaling—DRD4—conduct disorder	9.63e-05	0.00062	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—WASF1—conduct disorder	9.57e-05	0.000616	CbGpPWpGaD
Ergotamine—DRD2—GPCR ligand binding—HTR2A—conduct disorder	9.42e-05	0.000607	CbGpPWpGaD
Ergotamine—CYP3A4—Biological oxidations—COMT—conduct disorder	9.41e-05	0.000606	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—WASF1—conduct disorder	9.37e-05	0.000603	CbGpPWpGaD
Ergotamine—CYP3A4—Biological oxidations—MAOA—conduct disorder	9.34e-05	0.000602	CbGpPWpGaD
Ergotamine—DRD2—Circadian rythm related genes—EP300—conduct disorder	9.34e-05	0.000602	CbGpPWpGaD
Ergotamine—HTR1A—GPCR downstream signaling—DRD4—conduct disorder	9.29e-05	0.000599	CbGpPWpGaD
Ergotamine—CYP3A4—Metapathway biotransformation—COMT—conduct disorder	9.28e-05	0.000598	CbGpPWpGaD
Ergotamine—HTR2C—GPCR downstream signaling—DRD4—conduct disorder	9.25e-05	0.000596	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—CGA—conduct disorder	9.22e-05	0.000594	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR ligand binding—HTR2A—conduct disorder	9.08e-05	0.000585	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—CGA—conduct disorder	8.9e-05	0.000573	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—CGA—conduct disorder	8.86e-05	0.00057	CbGpPWpGaD
Ergotamine—ADRA1B—GPCR downstream signaling—DRD4—conduct disorder	8.85e-05	0.00057	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—WASF1—conduct disorder	8.8e-05	0.000567	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—DRD4—conduct disorder	8.74e-05	0.000563	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CGA—conduct disorder	8.48e-05	0.000546	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—DRD4—conduct disorder	8.44e-05	0.000544	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR ligand binding—HTR2A—conduct disorder	8.43e-05	0.000543	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—DRD4—conduct disorder	8.4e-05	0.000541	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—CGA—conduct disorder	8.37e-05	0.000539	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—WASF1—conduct disorder	8.19e-05	0.000527	CbGpPWpGaD
Ergotamine—DRD2—GPCR downstream signaling—DRD4—conduct disorder	8.16e-05	0.000526	CbGpPWpGaD
Ergotamine—HTR1D—GPCR downstream signaling—HTR2A—conduct disorder	8.13e-05	0.000524	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—DRD4—conduct disorder	8.04e-05	0.000518	CbGpPWpGaD
Ergotamine—HTR2A—GPCR downstream signaling—DRD4—conduct disorder	8.03e-05	0.000517	CbGpPWpGaD
Ergotamine—HTR1B—GPCR downstream signaling—HTR2A—conduct disorder	7.96e-05	0.000513	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR downstream signaling—DRD4—conduct disorder	7.86e-05	0.000506	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CGA—conduct disorder	7.82e-05	0.000503	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CGA—conduct disorder	7.69e-05	0.000495	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CGA—conduct disorder	7.53e-05	0.000485	CbGpPWpGaD
Ergotamine—HTR2B—GPCR downstream signaling—HTR2A—conduct disorder	7.48e-05	0.000482	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—DRD4—conduct disorder	7.41e-05	0.000477	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—WASF1—conduct disorder	7.39e-05	0.000476	CbGpPWpGaD
Ergotamine—HTR1D—Signaling by GPCR—HTR2A—conduct disorder	7.38e-05	0.000475	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—DRD4—conduct disorder	7.3e-05	0.00047	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—DRD4—conduct disorder	7.29e-05	0.00047	CbGpPWpGaD
Ergotamine—HTR1B—Signaling by GPCR—HTR2A—conduct disorder	7.23e-05	0.000466	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—DRD4—conduct disorder	7.14e-05	0.00046	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—WASF1—conduct disorder	7.13e-05	0.00046	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—WASF1—conduct disorder	7.1e-05	0.000457	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CGA—conduct disorder	7e-05	0.000451	CbGpPWpGaD
Ergotamine—ADRA1D—GPCR downstream signaling—HTR2A—conduct disorder	6.96e-05	0.000448	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—HTR2A—conduct disorder	6.82e-05	0.000439	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—WASF1—conduct disorder	6.79e-05	0.000438	CbGpPWpGaD
Ergotamine—HTR2B—Signaling by GPCR—HTR2A—conduct disorder	6.79e-05	0.000437	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—DRD4—conduct disorder	6.68e-05	0.00043	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—DRD4—conduct disorder	6.63e-05	0.000427	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—DRD4—conduct disorder	6.54e-05	0.000422	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—HTR2A—conduct disorder	6.43e-05	0.000414	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—HTR2A—conduct disorder	6.32e-05	0.000407	CbGpPWpGaD
Ergotamine—ADRA2B—GPCR downstream signaling—HTR2A—conduct disorder	6.28e-05	0.000405	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—WASF1—conduct disorder	6.26e-05	0.000403	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—WASF1—conduct disorder	6.16e-05	0.000397	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—DRD4—conduct disorder	6.15e-05	0.000396	CbGpPWpGaD
Ergotamine—HTR1A—GPCR downstream signaling—HTR2A—conduct disorder	6.06e-05	0.000391	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—WASF1—conduct disorder	6.04e-05	0.000389	CbGpPWpGaD
Ergotamine—HTR2C—GPCR downstream signaling—HTR2A—conduct disorder	6.03e-05	0.000389	CbGpPWpGaD
Ergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	6.02e-05	0.000388	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—CGA—conduct disorder	5.79e-05	0.000373	CbGpPWpGaD
Ergotamine—ADRA1B—GPCR downstream signaling—HTR2A—conduct disorder	5.77e-05	0.000372	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—DRD4—conduct disorder	5.72e-05	0.000368	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—HTR2A—conduct disorder	5.7e-05	0.000367	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—WASF1—conduct disorder	5.61e-05	0.000361	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—HTR2A—conduct disorder	5.51e-05	0.000355	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—HTR2A—conduct disorder	5.48e-05	0.000353	CbGpPWpGaD
Ergotamine—DRD2—GPCR downstream signaling—HTR2A—conduct disorder	5.32e-05	0.000343	CbGpPWpGaD
Ergotamine—ADRA2B—Hemostasis—EP300—conduct disorder	5.27e-05	0.000339	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—HTR2A—conduct disorder	5.24e-05	0.000338	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—DRD4—conduct disorder	5.16e-05	0.000333	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR downstream signaling—HTR2A—conduct disorder	5.13e-05	0.00033	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—DRD4—conduct disorder	4.99e-05	0.000321	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—DRD4—conduct disorder	4.96e-05	0.000319	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—HTR2A—conduct disorder	4.83e-05	0.000311	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—HTR2A—conduct disorder	4.77e-05	0.000307	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—DRD4—conduct disorder	4.75e-05	0.000306	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—HTR2A—conduct disorder	4.66e-05	0.0003	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—CGA—conduct disorder	4.62e-05	0.000298	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—DRD4—conduct disorder	4.38e-05	0.000282	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—HTR2A—conduct disorder	4.36e-05	0.000281	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—HTR2A—conduct disorder	4.33e-05	0.000279	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—DRD4—conduct disorder	4.31e-05	0.000277	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—HTR2A—conduct disorder	4.27e-05	0.000275	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—DRD4—conduct disorder	4.22e-05	0.000272	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—HTR2A—conduct disorder	4.01e-05	0.000258	CbGpPWpGaD
Ergotamine—ADRA2A—Hemostasis—EP300—conduct disorder	4e-05	0.000257	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—DRD4—conduct disorder	3.92e-05	0.000252	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—COMT—conduct disorder	3.78e-05	0.000243	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—MAOA—conduct disorder	3.75e-05	0.000242	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—HTR2A—conduct disorder	3.73e-05	0.00024	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—EP300—conduct disorder	3.61e-05	0.000233	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CGA—conduct disorder	3.57e-05	0.00023	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—EP300—conduct disorder	3.41e-05	0.00022	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—HTR2A—conduct disorder	3.37e-05	0.000217	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—HTR2A—conduct disorder	3.25e-05	0.00021	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—HTR2A—conduct disorder	3.24e-05	0.000208	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—HTR2A—conduct disorder	3.1e-05	0.0002	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—HTR2A—conduct disorder	2.86e-05	0.000184	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—HTR2A—conduct disorder	2.75e-05	0.000177	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—COMT—conduct disorder	2.61e-05	0.000168	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—MAOA—conduct disorder	2.59e-05	0.000167	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—HTR2A—conduct disorder	2.56e-05	0.000165	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—EP300—conduct disorder	2.31e-05	0.000149	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—EP300—conduct disorder	2.26e-05	0.000146	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—EP300—conduct disorder	2.13e-05	0.000137	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—COMT—conduct disorder	2.09e-05	0.000134	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—MAOA—conduct disorder	2.07e-05	0.000133	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—conduct disorder	2.01e-05	0.000129	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—EP300—conduct disorder	1.98e-05	0.000127	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—EP300—conduct disorder	1.79e-05	0.000115	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—EP300—conduct disorder	1.72e-05	0.000111	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—EP300—conduct disorder	1.71e-05	0.00011	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—EP300—conduct disorder	1.64e-05	0.000106	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—EP300—conduct disorder	1.62e-05	0.000104	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—COMT—conduct disorder	1.61e-05	0.000104	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—MAOA—conduct disorder	1.6e-05	0.000103	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—EP300—conduct disorder	1.51e-05	9.75e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—EP300—conduct disorder	1.49e-05	9.59e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—EP300—conduct disorder	1.46e-05	9.39e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—EP300—conduct disorder	1.35e-05	8.72e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—EP300—conduct disorder	1.12e-05	7.21e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—EP300—conduct disorder	8.94e-06	5.76e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—EP300—conduct disorder	6.9e-06	4.44e-05	CbGpPWpGaD
